Delivery Order SPE2DB24D1205-SPE2DB25FCYXJ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $13,230.97 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Gemtesa (mirabegron) is a beta-3 agonist used to treat overactive bladder,...
- The Defense Logistics Agency awarded a $45.5K delivery order to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (30-count units) on August 4, 2025, with completion scheduled for August 5, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) on August 8, 2025, with a ceiling value of $3,831.81 and an ultimate completion date of August 11, 2025. This non-set-aside, competitively awarded delivery order utilizes firm fixed pricing and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $4,983.09 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Gemtesa 75 mg tablets (90-count units), with completion scheduled for July 29, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle running through December 2026. The...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,779.72 for 90 tablets of Gemtesa 75 mg on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical product will be...
- The Defense Logistics Agency awarded a delivery order valued at $13,881.40 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90 count) on July 25, 2025, with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare...
- The Defense Logistics Agency awarded a delivery order valued at $43,249.13 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (30-count packages) on July 18, 2025, with an ultimate completion date of July 21, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. Gemtesa is a prescription medication used in the treatment of overactive...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) valued at $10,304.26. This is a firm fixed-price delivery order with no set-aside designation, reflecting competitive procurement practices. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a delivery order valued at $8,344.44 to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Gemtesa 75 mg tablets in quantities of 90 units. This competitive delivery order is structured as a firm fixed price contract with an ultimate completion date of July 22, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Gemtesa is a prescription medication used in the treatment of overactive bladder,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $24,880.45 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count supply) on July 29, 2025, with an ultimate completion date of July 30, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. The contract is executed as a child order under AmerisourceBergen's larger...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCYXJDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) with a ceiling value of $52,500.45. This is a firm fixed price delivery order with an ultimate completion date of July 28, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is issued under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which provides comprehensive global pharmaceutical support for military healthcare programs. As a major pharmaceutical distributor, AmerisourceBergen Drug Corp serves critical federal medical procurement needs across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. Gemtesa (mirabegron) is a medication used to treat symptoms of overactive bladder, reflecting the breadth of therapeutic areas supported through the company's federal supply contracts. The DLA's Pharmaceutical Prime Vendor Global Program Generation V initiative, under which this delivery order operates, is designed to enable flexible pharmaceutical sourcing across multiple regions and contractors to ensure reliable medical supply availability for military and veteran healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $52.5k | 7/25/25 |